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Abstract 
Background  
Arterial stiffness (AS), as pulse wave velocity (PWV), is a powerful independent 
predictor of cardiovascular events and commonly complicates type 2 diabetes (T2D). 
This trial aims to test if AS, measured by the VaSera machine as cardio-ankle 
vascular index (CAVI) and by Arteriograph measuring central PWV, can be reduced 
by spironolactone and/or inorganic nitrate from beetroot juice independently of blood 
pressure (BP) in those with or at risk of T2D. 
Methods 
A factorial design, double blind, randomised controlled trial in 18-80 year old men 
and women clinically diagnosed with T2D or at risk of it (body mass index (BMI) > 
27 kg.m-2, positive family history or glucose intolerance). The study lasts up to 36 
weeks with daily intervention of either ≤50 mg spironolactone (intervention) or ≤ 16 
mg doxazosin (control), and beetroot juice with ≤400 mg (9 mmol) inorganic nitrate 
(intervention) or placebo beetroot juice, 0 mg nitrate (control).  Non-invasive AS 
measurements are carried out at baseline and then at 12-week intervals thereafter. 
Results 
To date, 95 participants have been consented and screened, 19 of these were not 
suitable or not willing to participate so that 73 have been randomised with 9 
participants screened as eligible and awaiting randomisation.  53 participants have 
completed the study.  Mean baseline and follow up measures of cardiac-ankle and 
cardiac-aortic bifurcation PWV and BP have been straightforward.  
Conclusion 
This is a proof-of-principle trial to alter AS independent of BP in a patient sample at 
high cardiovascular risk.  [247 words] 
  
Key words: Arterial stiffness; pulse wave velocity (PWV); cardio-ankle vascular 
index (CAVI); spironolactone; beetroot; nitrate. 
 
Background 
Type 2 diabetes mellitus (T2D) is a chronic disease, possibly due to excess fat 
accumulation with inflammatory damage to blood vessels, currently diagnosed with 
elevated blood glucose. The rapid increase in T2D worldwide is due to both the 
obesity epidemic and the aging population [1]. Cardiovascular complications of T2D 
tend to emerge relatively early, with 54% of deaths in T2D patients being attributed to 
cardiovascular disease [2]. In these patients, deposition of collagen matrixes in the 
media of blood vessels is thought to cause arterial stiffening [3].  
Aldosterone, the mineralocorticoid steroid hormone produced by the adrenal gland 
increasing salt and water retention, is involved in blood pressure (BP) regulation. 
Increasing evidence suggests that aldosterone causes collagen deposition in vascular 
walls [4, 5], hence promoting arterial stiffening. Spironolactone is a mineralocorticoid 
receptor antagonist used primarily as a diuretic, but noted for its ability to control BP, 
although not formally licensed for this indication [6]. Although its BP lowering 
effects are established, the drug has also been shown to reduce arterial stiffening, 
measured as pulse wave velocity (PWV) in hypertensive diabetic patients in a small 
study (n= 10); however, how far this PWV effect was related to BP reduction is 
unclear [7]. A longer term study reported that spironolactone at 25 mg/day for 40 
weeks reduced PWV independently of BP, although the latter still fell by 11 ± 12 
mmHg, in addition to a reduction in left ventricular mass [8].   
Improving vascular function by dietary means is becoming increasingly appealing for 
the public and clinicians alike. Foods rich in inorganic nitrate, such as spinach and 
beetroot have been shown to exhibit beneficial effects on the vascular system such as 
improving endothelial dysfunction [11], inhibiting platelet aggregation [9] and 
adhesion [10] in the endothelium and improving endothelial dysfunction [11]. Further, 
nitrates are becoming an established means of reducing BP, as found in short term 
randomised controlled trials (RCTs) [12-15].  Nitrate containing foods are thought to 
work by uptake of their naturally occurring nitrate into the entero- salivary circulation 
and subsequent conversion via the nitrate- nitrite- nitric oxide (NO) pathway, with 
NO, the ubiquitous vasodilator from endothelium, mediating the reduction in BP. 
Less work, however, has investigated the effect of dietary nitrate on arterial 
stiffening; an acute investigation using a high nitrate spinach meal did not alter PWV 
in healthy volunteers [16], however a study in drug naive grade one hypertensive 
patients did show a reduction in PWV after beetroot juice ingestion [17]. 
PWV has long been an established technique of assessing arterial stiffness. While 
applanation tonometry has been the most widely used method to measure what is 
known as carotid-femoral (cf) PWV [18], as those vessel sites are used for 
measurement, other less intrusive means are now available. These cuff based 
measurements, Arteriograph and Mobil-o-graph (which measure central or aortic (ao) 
PWV) are becoming increasingly popular due to ease of application, the reduced 
amount of training required, comfort for patients and seemingly comparing well 
against other methods, including magnetic resonance (MR), once arterial path length 
is calibrated [19]. An alternative device, the VaSera machine (by Fukuda Denshi) 
measures cardio- ankle PWV, expressed as the cardio- ankle vascular index (CAVI) 
to reduce dependence from ambient BP [20]. 
Here, we describe the design of our VaSera trial, assessing the efficacy of 
spironolactone and dietary nitrate (as beetroot juice) to alter arterial stiffness, 
primarily as measured by CAVI, independently of BP. 
 
Study design and methods 
Overall design 
The objective is to test, in a factorial designed RCT, whether spironolactone, up to 
50mg/ day and/or dietary nitrate, up to 9 mmol nitrate per day as a 70mL shot of 
‘Beet-it’ or ‘Beet-it Sport’ beetroot juice, (compared with up to 16mg/ day doxazosin 
and identical 70mL nitrate free juice respectively) reduces arterial stiffness after up to 
6 months, measured as CAVI  by the VaSera machine and as aoPWV by the 
Arteriograph, in patients diagnosed with or at risk of T2D (see Table 1). 
After the initial consenting and screening/ familiarisation visit, visit 1 (V1), if the 
criteria were met (as below), patients were invited to return for a randomisation visit, 
visit 2 (V2), to be allocated to one of the four groups (Table 1). Participants and those 
running the study are blinded to the intervention allocation, which was block 
randomised in groups of six, performed and held by an independent party. At V2 
baseline vascular measurements (CAVI, PWV and echocardiogram) are performed, in 
addition to baseline blood, spot urine and 24 hour urine collection for various 
biochemical assessments (HbA1c, glucose, renal function as well as a urinary steroid 
metabolite profile); 24 hour BP and PWV monitoring is also performed before the 
intervention is started. Study medication and juice is given at this visit; titrated up to 
25 mg/ day spironolactone or 4 mg/ day doxazosin and beetroot juice with 4.5 mmol 
nitrate/ day or control 0 mmol nitrate/ day. A check up visit for renal function and well 
being occurs 2 weeks into the study (V3), then again with PWV and BP at 8 weeks 
after randomisation (V4). At 12 weeks post randomisation (V5) a further visit with 
vascular measures and detailed biochemical assessment and repeat 24 hour monitoring 
is carried out as at V2. At this visit, the medication dose should be doubled to 50 mg/ 
day (spironolactone) or 16 mg/ day (doxazosin) with a more concentrated beetroot 
juice (9 mmol nitrate /day or control, 0 mmol nitrate/ day), depending on biochemical 
and BP data at check up visits. Visits 6 and 7 (V6, V7 at 24 and 36 weeks 
respectively), follow the same assessments as at V2 and V5; at one of these visits the 
study is terminated, depending on the length agreed with the participant at the start of 
the study, with study duration being shorter as recruitment nears its end (Figure 1).  
The study was reviewed and approved by Central London National Research Ethics 
Service (NRES). 
 
Participant eligibility 
We aim to randomise up to 120 people with or at risk of T2D from the local 
community (South London, UK) with a broad inclusion criteria for eligibility. 
Recruitment is carried out through referral from hypertension and diabetes clinics in 
secondary care, appropriate contact with local health centers and general practices and 
advertisements. The aim is to recruit approximately equal numbers of men and women 
and equal numbers with T2D and those at risk of T2D. The following inclusion and 
exclusion criteria are followed on recruitment of participants. 
Inclusion criteria: 
- Age 18- 80 years 
- Previously clinically diagnosed T2D or at risk of T2D (body mass index (BMI) ≥ 27 
kg.m-2, a positive family history or glucose intolerance 2 hour after (75 g challenge) 
- Ability to understand the protocol and willingness to comply with it 
Exclusion criteria: 
- Chronic illness of any type that may interfere with participation  
- Previous adverse reaction to spironolactone or doxazosin  
- Known allergy to beetroot 
- Impaired renal function (eGFR < 45 mL.min-1)  
- HbA1c > 11% or fasting random glucose > 12 mmol.L-1 
- Being pregnant or breastfeeding for the duration of the study  
- Atrial fibrillation 
 
Arterial stiffness techniques 
AS is measured by a variety of devices, which have demonstrated good repeatability 
(between V1 and V2) at V1, V2, V5, V6, and V7 to assess the efficacy of the 
interventions on AS. Participants are measured using: 
i) The VaSera VS-1500N (Fukuda Denshi co., Ltd, Japan), a four- cuff device 
(placed over the upper arms, as with a standard BP cuff, and above both ankles) 
measuring stiffness from the heart to the ankles, using a microphone to detect aortic 
valve closure (the 2nd heart sound) expressed as CAVI a value calculated from PWV 
using the stiffness parameter, β. The CAVI formula (Figure 2), which greatly reduces 
the dependence of PWV on ambient BP, aims to give a BP independent estimate of 
arterial stiffness.  A change in CAVI is the primary outcome of the study. 
 
ii) The Arteriograph 24TM (Tensiomed Kft. Hungary), which measures aoPWV 
using a non invasive, one cuff method. The device uses the return time (difference 
between the first and reflected systolic peaks) and distance between sternal notch and 
symphsis to calculate aoPWV. The device has been calibrated against cfPWV and MR 
derived PWV with length calibration [19]. 
 
 
iii) The Vicorder® (SMT medical GmbH & Co. KG, Germany) is another non 
invasive cuff based technique to measure carotid-femoral cfPWV; one cuff, a small 
band on the maximal carotid pulsation on one side of the neck only to detect carotid 
pulse waves (and easily striped off if the participant feels claustrophobic), the other 
around the upper thigh to detect femoral pulse waves.   
 
Hypothesis 
We hypothesise that between spironolactone and doxazosin (which both lower BP), 
spironolactone will further alter CAVI by ≥ 0.4 units and CAVI’s cardiac-brachial 
PWV and aoPWV by ≥ 0.5 ms-1 with a minimal difference in BP. Further, we 
anticipate that the oral inorganic nitrate supplement as the beetroot juice will promote 
longer term generation of vascular nitric oxide (measurable as increased circulating 
nitrite) and also, independently of the drug comparison arm, reduce PWV by ≥ 0.5 ms-
1, again after adjusting for any change in BP, compared with the effect of the control 
juice with no nitrate. We hypothesize that there will be an additive effect ≥ 1 ms-1 of 
both the spironolactone and nitrate in the combined arm, compared with neither on the 
assessed vascular parameters. 
 
Statistical considerations & power 
Sufficient data were not available from which to calculate sample sizes directly for 
CAVI only. Therefore to detect a reduction in CAVI, of 20% (± 8% standard 
deviation) with minimum 80% power, at p <0.05 over 6 months of on the study, we 
based calculations on previous short term studies on BP with beetroot juice [21, 22] 
and a long term study on aoPWV and spironolactone [8], at similar power, and 
estimated that 24 participants per box of the 2x2 table are required. We therefore aim 
to recruit 30 patients per group based on a 20% drop out rate, to generate 25 people 
per box to finish the trial.  
  
Results 
Participant descriptives 
On writing this manuscript, 95 patients had been consented, of which 7 were 
unsuitable due to uncontrolled diabetes, adverse reactions to the study interventions 
and being unable to commit. A dropout rate of 14% between consent and 
randomisation and 7% after randomisation has been observed, see CONSORT 
diagram, Figure 3.  To that date, 53 participants have completed the entire study. The 
baseline descriptives of participants who entered to date at randomisation in Table 2 
(n=73) show that we have recruited slightly more men than women, and more with 
clinically diagnosed T2D than those at risk. We classified ethnicity by local 
populations known to be at higher risk of diabetes (West African and African 
Caribbean, with relatively few South Asian people living locally).  
Considering the associations with vascular health, despite recruiting participants with 
or at risk of T2D the mean blood pressure is not elevated; our participants are not 
clinically defined as hypertensive. However, the mean PWV and CAVI of the 
participants, as measured by all methods suggest there is some stiffening of the 
arteries, for the men assessed this is even above the reference value considering their 
age [23]. 
   
Study interventions 
Of the 73 participants who have been randomised onto the study, there have been 103 
reported adverse events (from 57 participants) post randomisation.  Of these events 23 
(from 12 participants) are considered to be attributed to the interventions, with 
common reported events being dizziness/lethargy (13% of randomised participants), 
nausea/ sickness or diarrhoea (4%), incontinence (4%), rash (3%).  No participants 
have dropped out of the study due to reported adverse effects from the interventions; 
all effects were controlled by reduction in dose or by stopping one of the interventions.  
In addition to these there have been six reported serious adverse events post 
randomisation with none of these being attributed to the interventions. 
 
Conclusions 
This study was designed to investigate the effect of inorganic nitrate from beetroot 
juice and spironolactone on arterial stiffness, independent of blood pressure in those 
with or at risk of T2D.  To date this study has proven easy to recruit for with a low 
dropout rate (7% after randomisation).  Participants have been happy taking the 
interventions with minimal consequential ill effects, and have generally been 
committed to the study for the duration.   
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TABLES AND FIGURES 
 
Table 1.  Factorial design of the VaSera trial, with number of participants to be 
randomised to each arm 
 Nitrate juice 
(4.5– 9 mmol 
nitrate/day) 
Placebo juice 
(0 mmol 
nitrate/day) 
Total 
(n) 
Spironolactone 
(12.5- 50 mg/day) 
25- 30 25- 30 50- 60 
Doxazosin 
(4- 16 mg/ day) 
25- 30 25- 30 50- 60 
Total (n) 50- 60 50- 60 100- 120 
 
 
 
Table 2.  Baseline characteristics of 52 participants randomised to date 
Parameter  Men ± SD Women ± SD 
n (%) 62 38 
Age (years)  58 ± 13 61 ± 11 
Weight (kg) 96.3 ± 19 87.5 ± 19.3 
BMI (kg.m-2)  32 ± 6 34 ± 7  
Waist circumference (cm) 109 ± 12  107 ± 16 
Type 2 diabetes (%) 73 75 
Ethnicity (%): European   60 54 
                        African Caribbean     4 18 
                        West African 4 18 
                         Other 31 11 
SBP  (mm Hg)  133 ± 17 129 ± 16 
DBP (mm Hg) 78 ± 10 74 ± 10 
Pulse (BPM) 70 ± 12 69 ± 12 
aoSBP (mm Hg) 128 ± 22 125 ± 18 
aoAIX (%) 25 ± 17 31 ± 14 
 aoPWV  (m.s-1)  9.21 ± 1.81 9.31 ± 1.67 
cfPWV  (m.s-1) a 8.90 ± 1.60 8.78 ± 1.37 
CAVI (units)  8.40 ± 1.45 7.81 ± 0.95 
a men, n=27 and women, n=21 for this measurement 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
BPM, beats per minute; ao, aortic (central); cf, carotid-femoral; ca, cardio-ankle; 
CAVI, cardio-ankle vascular index. 
 
Figure 1.  Study flow diagram 
a Multiple arterial stiffness measurements; central (ao) pulse wave velocity (PWV) by 
Arteriograph, carotid femoral (cf)PWV by Vicorder and cardio-ankle vascular index 
(CAVI) by VaSera, in addition to echocardiogram and blood pressure monitoring. 
b One off aoPWV by Arteriograph  
PWV; pulse wave velocity, BP; blood pressure 
 
Figure 2.  Formulas to derive cardio- ankle vascular index (CAVI) 
β; stiffness parameter, Ps; systolic pressure, Pd; diastolic pressure, D; diameter, PWV; 
pulse wave velocity, P; pulse pressure, ρ; blood density, CAVI; cardio-ankle vascular 
index  
 
 
Figure 3.  CONSORT (consolidated standards of reporting trials) diagram 
Based on inclusion/ exclusion criteria patients are diagnosed with or at risk of type 2 
diabetes (with BMI≥ 27 kg.m-2 or glucose intolerance). HbA1c are to be < 11% or 
fasting glucose <12 mmol.L-1 with good renal function (eGFR> 45mL.min-1) 
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